|
Market Closed -
Other stock markets
|
Pre-market 12:05:23 | |||
| 74.41 USD | +5.20% |
|
69.88 | -6.08% |
Business description: Arrowhead Pharmaceuticals, Inc.
Number of employees: 711
Sales by Activity: Arrowhead Pharmaceuticals, Inc.
| Fiscal Period: September | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Nanotechnology | 138M | 243M | 241M | - | 829M |
Geographical breakdown of sales: Arrowhead Pharmaceuticals, Inc.
| Fiscal Period: September | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 138M | 243M | 241M | - | 829M |
Executive Committee: Arrowhead Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 30/11/2007 | |
Daniel Apel
DFI | Director of Finance/CFO | - | 12/05/2025 |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2022 |
Patrick O'brien
CMP | Compliance Officer | 62 | 30/11/2014 |
James Hamilton
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2025 |
Composition of the Board of Directors: Arrowhead Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | - | |
Mauro Ferrari
BRD | Director/Board Member | 66 | 18/08/2010 |
Michael Perry
BRD | Director/Board Member | 66 | 18/12/2011 |
William Waddill
BRD | Director/Board Member | 69 | 31/12/2017 |
Adeoye Olukotun
BRD | Director/Board Member | 81 | 31/08/2020 |
| Director/Board Member | 62 | 01/05/2022 | |
Hong Bo Lu
BRD | Director/Board Member | 55 | 31/03/2024 |
Company details: Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard
91105, Pasadena
+626 304 3400
http://www.arrowheadpharma.com
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.20% | -1.00% | +344.50% | +110.67% | 10.48B | |
| +0.59% | +1.85% | +54.25% | +110.86% | 55.58B | |
| +0.03% | +0.33% | +49.22% | +43.94% | 43.47B | |
| +3.93% | -0.06% | -15.10% | -18.04% | 22.64B | |
| +5.27% | -7.82% | -1.29% | +388.48% | 20.96B | |
| +3.81% | -5.07% | +12.00% | -29.52% | 15.79B | |
| +0.42% | +0.50% | +9.10% | -40.04% | 15.3B | |
| +1.75% | +1.92% | +29.13% | +178.65% | 13.45B | |
| +5.27% | +5.54% | +14.25% | - | 11.74B | |
| -5.27% | -0.43% | +87.77% | +208.02% | 10.96B | |
| Average | +2.10% | -0.48% | +58.39% | +105.89% | 22.04B | |
| Weighted average by Cap. | +1.73% | +0.68% | +46.50% | +98.60% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARWR Stock
- Company Arrowhead Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition